Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050243
Chunk: 2

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 2
---
 pay them for these and related advisory services an estimated fee of $30,000 and reimburse
them for reasonable out-of-pocket expenses. We have also agreed to indemnify MacKenzie Partners and certain related persons against certain
liabilities relating to or arising out of MacKenzie Partners’ engagement.

<div align='center'>7 Penn Plaza
New York, New York 10001

Toll-Free: 1-800-322-2885

Or

Email: proxy@MacKenziePartners.com</div>

ADDITIONAL QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND VOTING

| Q: | Is my vote important? |

| A: | Yes, and your vote will be particularly important                                                                                             
 this year. As you may know, ADAR1, a 13.3% stockholder of the Company, publicly announced its intention to withhold votes with respect        
 to the election of Mary Ann Gray, Ph.D., and Alpna Seth, Ph.D., to the Board at the Annual Meeting. The Board unanimously recommends a        
 vote “FOR” each of the Board’s three Class II director nominees, including Dr. Gray and Dr. Seth.                                             
 Even                                                                                                                                          
 if you plan to attend the Annual Meeting, we recommend that you also submit your proxy or voting instructions or vote by telephone or         
 through the internet in advance of the Annual Meeting so that your vote will be counted if you later decide not to attend the Annual Meeting. |

| Q: | How does the Board recommend I vote with respect to the election the three director nominees?                                  |
| A: | Our Board unanimously recommends that you vote “FOR” each of the Board’s three                                                 
 Class II director nominees.                                                                                                    |
|    | We describe this matter and the Board’s reason for its recommendation on pages 9 and 10, and elsewhere in the Proxy Statement. |

| On the other matters scheduled for a vote, the Board unanimously 
 recommends you vote:                                             |

| · | “FOR” ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and |
|:--|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| · | “FOR” advisory approval of our named executive officer compensation, as disclosed in the Proxy Statement.                                                           |

| Q: | Will there be a proxy contest at the Annual Meeting?                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| A: | ADAR1 has publicly announced its intention